Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-753 versus Yescarta in relapsed or refractory large B-cell lymphoma after first-line therapy
2025-524403-80-00Phase 3Authorised
- Sponsor
- Kite Pharma
- Start
- Jul 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing KITE-753 with Axicabtagene ciloleucel (Yescarta) (2 arms). Primary endpoints: Six-month complete response (CR) rate and Event-free survival (EFS). Planned start Jul 2026; status: authorised.
02
Drugs
KITE-753axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2025-524403-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524403-80-00.